Doctors in India can be disciplined for taking gifts from drug companies. The companies handing them out, so far, cannot be punished the same way. That gap sits at the centre of a new Supreme Court direction on pharma freebies to doctors: the Union government has been told to set up a committee to recommend statutory rules on unethical drug-marketing practices.
The direction came from a bench of Justice Vikram Nath and Justice Sandeep Mehta in a writ petition filed by the Federation of Medical and Sales Representatives Associations of India (W.P.(C) No. 323/2021), and was reported on 8 October 2026. The panel is meant to hear suggestions and representations and then give recommendations to the Union. It is a step towards a law, not a law itself, and that distinction matters for everyone from prescribing physicians to the pharma companies that sell to them.
Key takeaways: what the Supreme Court has and has not done
- What it ordered: the Centre must constitute a committee to examine and recommend regulations on unethical pharma marketing.
- What it did not do: it has not itself made the marketing code legally binding, and no penalties on companies have been created yet.
- Timeline: the Solicitor General reportedly told the Court the committee would have three members and report within two months. The matter returns on 29 January to examine the Union’s compliance affidavit.
- Meanwhile: the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 continues to apply.
Why the Court stepped in
The petition argues that heavy promotional spending by drug makers is designed to push prescriptions upward, leading to over-prescription and harming patients’ right to health under Article 21 of the Constitution. The petitioners say voluntary self-regulation has failed to stop it.
The bench had earlier asked a pointed question: does the UCPMP have adequate enforcement mechanisms, and does the government intend to give it statutory backing? Without government control, the Court observed, a regime described as mandatory could end up almost voluntary. Orders were reserved on 8 September 2026 after both sides were heard, according to court reporting.
A code that nobody is compelled to follow, and that has no consequences for breach, protects neither patients nor honest companies.
That line is our paraphrase of the concern the petitioners put before the Court, not a quotation from the bench. In our assessment, it captures why the enforcement question, rather than the content of the code, drove this litigation.
The asymmetry at the heart of the case
The Union’s affidavit dated 17 August 2026 said the Departments of Pharmaceuticals, Health and Family Welfare, and Legal Affairs had deliberated on the issue. It pointed out that the existing framework already provides for disciplinary action against doctors who accept gifts, travel, hospitality or monetary grants from pharmaceutical companies. Regulating the companies themselves is the part still missing.
Senior Advocate Sanjay Parikh, for the petitioners, called this an asymmetry: doctors face penalties, while no statutory mechanism exists to penalise companies that offer the inducements. He urged the Court to direct a statutory framework or, failing that, to lay down interim guidelines. The Court chose the committee route instead.
The petitioners also questioned why a fresh committee was needed at all. They noted that a 2022 Union affidavit had already said a high-level committee was formed to examine a legally enforceable mechanism. Whether the new panel will move faster than its predecessor is the obvious open question.
What the UCPMP 2024 already says
The Department of Pharmaceuticals issued the UCPMP in March 2024 and extended it to medical device companies in September 2024. Its core rule is plain: offering personal benefits to healthcare professionals is strictly prohibited. Travel support is allowed only for events with a genuine educational purpose, and educational brand-reminder items are capped at a value of ₹1,000.
Alleged violations go to the Ethics Committee for Pharma Marketing Practices, whose penalties range from suspension to corrective actions, with an appeal to an Apex Committee under the Department. The Union has told the Court it is considering a parliamentary Standing Committee recommendation (the 45th Report on Health and Family Welfare) to make the code mandatory through legislation.
Background the Court was shown
The petition and the Union’s counter-affidavit both refer to the Central Board of Direct Taxes’ allegation against the makers of Dolo-650 of distributing roughly ₹1,000 crore in freebies to doctors. That is an allegation made in tax proceedings, not a finding by the Supreme Court in this case, and we report it as such.
The petitioners also relied on the Court’s 2022 ruling in Apex Laboratories Pvt. Ltd. v. Deputy Commissioner of Income Tax, which described the doctor-patient relationship as quasi-fiduciary and warned that company benefits could influence prescriptions, calling the pattern a “publicly injurious cycle”. Separately, the red warning on cough syrups for children is part of a wider national conversation about how medicines are prescribed and sold.
The sequence so far
- 2021: the Federation files W.P.(C) No. 323/2021 in the Supreme Court of India.
- 2022: the Union tells the Court a high-level committee has been formed to examine a legally enforceable mechanism.
- March 2024: the UCPMP 2024 is issued; in September 2024 it is extended to medical devices.
- 17 August 2026: the Union files an affidavit on inter-departmental deliberations.
- 8 September 2026: orders reserved after hearing both sides.
- 8 October 2026: direction to constitute the committee is reported.
- 29 January: next hearing on the Union’s compliance affidavit.
What this means for doctors, companies and patients
For doctors: nothing changes immediately. The existing rules on gifts and hospitality still apply, and the National Medical Commission has reportedly kept its 2023 Professional Conduct Regulations, which would have curbed branded-medicine prescribing, in abeyance. Doctors should keep records of any sponsored academic events they attend.
For pharma and device companies: the realistic risk is a future statute with penalties on the company side. Firms that already run clean compliance programmes and publish their spending will be better placed if disclosure becomes mandatory. We would expect compliance teams to start mapping their current doctor-engagement spending now.
For patients: the benefit, if any, is indirect. Stricter rules could reduce the influence of promotions on prescribing, but they will not by themselves lower drug prices or guarantee better prescribing. That is our assessment, not a claim made by the Court.
Regulatory scrutiny of the sector has been intensifying on several fronts. For related coverage, see how the Maharashtra FDA cancelled Cipla’s Pune warehouse licences, and browse our wider pharmaceutical news.
Frequently asked questions
What did the Supreme Court order on pharma freebies to doctors?
It directed the Union government to constitute a committee to consider suggestions and representations and recommend regulations on unethical marketing practices by pharmaceutical companies.
Is the UCPMP legally binding?
The UCPMP 2024 is issued by the Department of Pharmaceuticals and companies are required to submit self-declarations, but it is not a statute. The Court questioned whether it can be effective without enforcement, and the government says it is considering making it mandatory through law.
Can doctors in India accept gifts from drug companies?
No. The framework prohibits personal benefits, including gifts, hospitality and cash, and provides for disciplinary action against doctors who accept them. Travel is allowed only for genuine educational events.
How long will the committee take?
The Solicitor General reportedly said it would have three members and report within two months. The Court will next examine compliance on 29 January.
Will companies be punished?
Not yet. No statutory penalty on companies exists, which is exactly the gap the committee is expected to address. Any such penalty would need government action after the committee reports.
How we reported this: we compared the Union affidavit and court submissions as described in court reporting, the UCPMP 2024 text and Department of Pharmaceuticals material. Order details such as the committee’s composition were not publicly available when we published. Last updated: 8 October 2026. This article is news reporting and not legal or medical advice.